BioCentury
ARTICLE | Company News

Gilead submits sofosbuvir NDA

April 9, 2013 1:08 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) submitted an NDA to FDA for sofosbuvir to treat chronic HCV infection. The company said the application covers the use of sofosbuvir in combination with ribavirin as...